Label Claim Substantiation for Dietary Supplements

1. Regulatory Classification of Label Claims Under DSHEA

Label claims on dietary supplement products sold in the United States are governed primarily by the Dietary Supplement Health and Education Act of 1994 (DSHEA), the Federal Food, Drug, and Cosmetic Act (FD&C Act), and implementing regulations in Title 21 of the Code of Federal Regulations. DSHEA applies to finished dietary supplements — products intended for ingestion as a supplement to the diet, containing dietary ingredients such as vitamins, minerals, herbs, or botanicals. The claim category into which a statement falls determines the substantiation standard, the pre-marketing requirements, and the enforcement risk.

1.1 Nutrient Content Claims (21 CFR Part 101, Subpart D)

A nutrient content claim characterizes the level of a nutrient in a product relative to a Reference Daily Intake (RDI), Daily Value (DV), or other established standard. Permitted terms and their quantitative definitions are codified in 21 CFR §§ 101.54–101.67. Representative examples:

• "High in" / "Rich in" / "Excellent source of": ≥20% of the RDI or DV per reference amount customarily consumed (RACC) per serving. (21 CFR §101.54(b))
• "Good source of": 10–19% of the RDI or DV per RACC per serving. (21 CFR §101.54(c))
• "More" / "Fortified" / "Enriched" / "Added": ≥10% more of the RDI or DV per RACC per serving than the reference food. (21 CFR §101.54(e))
• "Low sodium": ≤140 mg per RACC and per 50 g. (21 CFR §101.61)
• "Fat-free": <0.5 g fat per RACC and per labeled serving. (21 CFR §101.62(b))

Nutrient content claims do not require pre-market notification or FDA authorization, but the product must satisfy the applicable quantitative definition before the term may appear on the label. Use of a term that does not meet its regulatory definition constitutes misbranding under 21 U.S.C. §343.

1.2 Structure/Function Claims (21 CFR §101.93; 21 U.S.C. §343(r)(6))

A structure/function claim describes the role of a nutrient or dietary ingredient in maintaining the normal structure or function of the body, or characterizes a documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function. Structure/function claims are the most commonly used claim category on finished dietary supplement labels. Three mandatory procedural requirements attach to their use under 21 CFR §101.93. These procedural requirements are separate from and do not substitute for the substantiation obligation, which is addressed in Section 2.

Post-marketing notification (30-day window). The manufacturer, packer, or distributor must notify FDA of the text of the claim no later than 30 days after the product is first marketed with that claim. This is a disclosure requirement — FDA does not review, approve, or authorize the claim in response to the notification. Submitting the notification does not establish that the claim is substantiated; it establishes only that FDA has been informed that the claim is in commercial use.

Required disclaimer. The label must bear the following statement verbatim, prominently, in boldface type, immediately adjacent to the claim: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." The disclaimer must appear each time the claim appears on the label. Printing the disclaimer confirms that the procedural requirement has been met; it does not confirm that the underlying claim is substantiated.

Truthfulness and substantiation. The claim must be truthful and not misleading, and the manufacturer must have competent and reliable scientific evidence supporting that conclusion at the time the claim is first made. This is the substantive obligation — separate from, and not satisfied by, the notification or disclaimer.

1.3 Health Claims (21 CFR Part 101, Subparts E and F)

A health claim describes a relationship between a food substance and a reduced risk of a disease or health-related condition. Health claims require pre-market authorization from FDA under 21 U.S.C. §343(r)(1)(B), based on a finding that the evidence meets the "significant scientific agreement" (SSA) standard among qualified experts. Authorized health claims are codified at 21 CFR Part 101, Subpart E.

Qualified health claims are a separate category permitted where the evidence is supportive but does not meet the SSA standard. Both authorized and qualified health claims require FDA authorization or, for qualified claims, a successful petition and enforcement discretion letter from FDA.

A health claim is not the same as a drug claim, though the consequences of making an unauthorized health claim can produce drug-claim exposure. A drug claim is one that causes a product to meet the statutory definition of a drug under 21 U.S.C. §321(g)(1)(B) — specifically, an article "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man." An unauthorized disease claim on a dietary supplement label may cause FDA to treat the product as an unapproved new drug, because the claim itself establishes the intent that the statutory drug definition requires. The regulatory distinction is that health claims are a specific authorized category under the FD&C Act; drug claims are the broader category that any unauthorized disease-related claim can produce. The practical consequence is the same: enforcement as an unapproved drug.

1.4 The Structure/Function to Disease Claim Boundary

The line between a permissible structure/function claim and an impermissible disease claim is the highest-risk area of label compliance for finished supplement manufacturers. FDA guidance (FDA, 2000) identifies the factors used to evaluate whether a statement is a disease claim: express mention of a disease by name; use of the name of a sign or symptom primarily associated with a disease; description of a role in a disease process; characterization of a mechanism by which the supplement acts on a disease; and use of a term synonymous with treatment or prevention of a disease in common usage.

Misclassifying a disease claim as a structure/function claim is not a labeling technicality. A product bearing an unauthorized disease claim is misbranded and may be treated as an unapproved new drug, exposing the manufacturer to injunction, seizure, consent decree, and criminal referral — consequences not avoided by the presence of the structure/function disclaimer.

FDA evaluates claim language in the full context of the label and accompanying advertising. The table below illustrates the boundary with examples.

2. The Competent and Reliable Scientific Evidence Standard

The substantiation standard for structure/function claims is "competent and reliable scientific evidence." This standard applies under both FDA regulations (21 CFR §101.93) for label claims and FTC regulations (16 CFR Part 255) for advertising claims. The FTC has defined it as "tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results" (FTC Dietary Supplements Guide, 2012). The same formulation applies to both agencies; the difference in practice is one of enforcement frequency and consequence, not of the stated standard.

2.1 Scientific Validity

The evidence must be methodologically sound. For efficacy claims directed at a human health benefit, the most probative evidence is from randomized, controlled, double-blind trials with adequate statistical power and pre-specified endpoints. Mechanistic studies, in vitro data, animal studies, and epidemiological studies may contribute to the overall evidence base but are generally insufficient standing alone to substantiate a specific efficacy claim in a defined human population.

2.2 Relevance to the Claim: Population, Dose, and Bridging

The ideal substantiation basis is a well-controlled clinical trial conducted in the healthy population to which the product is directed, at the dose and in the dosage form the product delivers. Where such evidence exists, the link between the evidence and the claim is direct and strong.

Bridging — the use of evidence generated under different conditions to support a claim for the product as marketed — is a recognized practice, but the permissibility and strength of each bridge must be established in the substantiation file with explicit documented reasoning. Three types of bridging are generally accepted when properly documented:

• Disease to healthy population: Evidence generated in a clinically deficient or disease population may support a structure/function claim for healthy individuals where the mechanism of action is clearly applicable to normal physiology, the claim language does not overstate the relevance of the disease-population evidence, and the dosage is appropriate for the healthy population context.
• Across dosage levels: Conclusions may be bridged across studies showing effects at different dosage levels, even if no single study used exactly the dose in the product, where the dose-response relationship is established or the product dose falls within the studied range and the direction of effect is consistent.
• Across dosage forms with equivalent absorption: Evidence generated for one dosage form may be bridged to another where the absorption mechanism is equivalent and bioavailability data supports the equivalence. A gummy formulation with materially lower bioavailability of the active compound than the tablet form studied cannot rely on tablet evidence without bioavailability bridging data.

Bridging that is not documented and reasoned in the substantiation file is not bridging — it is an evidence gap. The absence of documentation is itself the substantiation problem.

2.3 Ingredient and Form Specificity

Evidence generated on a proprietary branded ingredient does not automatically transfer to a different supplier's material of the same nominal type. The key question is whether the evidence was generated on material that is substantiation-relevant-equivalent to what the product delivers.

Where the ingredient is a well-characterized, chemically defined compound with no meaningful variability between compliant sources — ascorbic acid, for example — the published evidence base for the compound is generally available to any manufacturer using a specification-compliant material. Where the ingredient is a botanical extract or a material with variable active compound profiles across sources, evidence specificity requires more careful analysis. Botanical extracts present a specific form of substitution risk: two suppliers may both deliver material certified to the same total active content, while differing materially in the ratio or relative levels of the functional actives. A willow bark extract standardized to 25% salicin from one supplier may carry a meaningfully different active compound profile from another supplier's 25% salicin material if the extraction method, plant part, or standardization method differs. Where the specific compound ratios have been shown to affect activity, that difference constitutes a substantiation-relevant distinction.

FTC guidance addresses this exact scenario directly. Where an advertiser relies on clinical trials conducted on a botanical extract produced by one extraction method, and the marketed product uses a different extraction method that produces a measurably different chemical profile, the advertiser should not rely on those trials as substantiation (FTC, Health Products Compliance Guidance, 2022, Example 38). The National Advertising Division has applied the same reasoning in practice: in its 2023 review of MacuHealth's eye health supplements, NAD found that none of the studies submitted had been conducted on the product as currently formulated and marketed, and recommended that the claims relying on that evidence be discontinued (NAD Case #7226, MacuHealth LP, September 2023). Manufacturers who reduce the dose, substitute a different-sourced material, or reformulate into a delivery system with different bioavailability should treat those changes as substantiation events.

2.4 Totality of the Evidence

FDA and FTC evaluate the totality of relevant scientific evidence, not only studies that support the claim. A manufacturer cannot rely selectively on positive studies while disregarding negative or null results. Where the overall evidence base is mixed, the claim language must accurately characterize the state of the evidence. Where subsequent meta-analyses or systematic reviews revise the weight of evidence against a previously supported claim, the manufacturer has an obligation to reassess and, if necessary, revise or withdraw the claim.

2.5 The Role of Expert Evaluation and Expert Panels

The standard requires evaluation by persons qualified in the relevant scientific disciplines. A substantiation file assembled from published abstracts by regulatory or marketing personnel, without formal expert review of evidence quality and claim applicability, does not satisfy the standard.

A formal expert panel — of the type used in GRAS self-determinations and NDI notification dossiers, examining ingredient safety — is not required for structure/function claim substantiation. The regulatory requirement is for qualified expert evaluation, which may be satisfied by a single suitably credentialed expert. A formal panel may be warranted where the claim is complex or contested, or where the commercial risk of a challenge is material. Where a panel is used, its composition, credentials, process, and findings should be fully documented.

3. FDA Enforcement of Label Claim Requirements

FDA's primary enforcement mechanism for label claim violations is the warning letter, a public document demanding corrective action within a defined timeframe. Warning letters are issued for: structure/function claims that constitute unauthorized disease claims; failure to include the required disclaimer in the required format; structure/function claims without adequate substantiation; and labeling that is false or misleading under 21 U.S.C. §343(a).

Beyond the warning letter, FDA's enforcement tools include import alerts, seizure under 21 U.S.C. §334, injunctions under 21 U.S.C. §332, and referral to the Department of Justice for criminal prosecution under 21 U.S.C. §333. In the dietary supplement category, FDA has pursued consent decrees and injunctions against manufacturers making disease claims, including against products that bore the structure/function disclaimer.

The commercial consequences of enforcement extend beyond the regulatory response. FDA warning letters are public and indexed in FDA's database; they are reviewed by retail buyers, marketplace platforms, brokers, and third-party auditors. A warning letter for a disease claim can trigger Amazon de-listing, retail partner suspension, and consumer press coverage that persists beyond correction of the underlying violation.

3.1 Third-Party Accountability

A manufacturer's regulatory obligations attach to the product and its claims in commerce, regardless of which party in the distribution chain makes the claim. When a retailer, distributor, or online seller makes claims about a manufacturer's product that exceed what the manufacturer's labeling supports, the manufacturer may bear regulatory exposure if those claims constitute misbranding or drug claims for the product.

Manufacturers should include claim compliance requirements in retailer and distributor agreements, monitor third-party claims in commerce, and request corrections when third-party claims exceed the substantiated basis.

4. FTC Jurisdiction: Advertising and Digital Marketing

The Federal Trade Commission exercises jurisdiction over advertising for dietary supplements under Section 5 of the FTC Act (15 U.S.C. §45) and Section 12 (15 U.S.C. §52). FTC jurisdiction extends to any advertising reaching consumers in the United States, including television, print, digital advertising, websites, social media, influencer content, email marketing, and promotional materials distributed to the general public.

4.1 Scope of FTC Jurisdiction

Product websites, landing pages, and e-commerce listings are advertising subject to FTC jurisdiction. Social media posts by the brand or by paid influencers and endorsers are advertising subject to FTC jurisdiction, including posts on Instagram, TikTok, YouTube, and similar platforms. Email marketing to consumers is advertising subject to FTC jurisdiction.

Sales materials, trade presentations, and documents shared exclusively with professional buyers or distributors and not distributed to consumers are generally not consumer advertising. However, any document that reaches or is expected to reach consumers, or that a retailer uses to sell the product to consumers, may be treated as advertising. Scientific literature citations and white papers distributed only to healthcare professionals are generally not treated as consumer advertising, but claims in those documents may become actionable if used in consumer-facing contexts.

4.2 The FTC Substantiation Standard in Practice

The FTC standard for health-related advertising is "competent and reliable scientific evidence" — the same standard that applies at FDA and FTC to structure/function claims on labels. In practice, FTC enforcement actions in the dietary supplement category have interpreted this standard to require, for specific efficacy claims, at least one adequate and well-controlled human clinical trial (FTC, 2012). This is an enforcement practice standard, not a codified regulatory requirement, but it reflects the level of evidence the FTC has consistently required in consent orders and enforcement actions. FTC enforcement in this category has been more active and more financially consequential than FDA enforcement for similar claims, with civil penalties, disgorgement, and consumer redress orders reaching into the tens of millions of dollars for major actions.

However, the difference between FTC and FDA enforcement posture should not be mistaken for a difference in the substantiation standard itself. Website advertising and social media content are frequently more aggressive with implied claims than product labels — this is a compliance gap, not a reflection of a more permissive environment. FTC has specifically cited digital advertising and website content as vectors for deceptive health claims in multiple enforcement actions against products whose labels were within FDA compliance.

4.3 Implied Claims and the Totality of Advertising

FTC evaluates claims in the context in which they appear, including implied claims that a reasonable consumer would take from the advertising as a whole. A series of individually defensible wellness statements may collectively constitute an implied disease prevention or treatment claim. Testimonials and before-and-after representations create implied efficacy claims subject to the same substantiation standard as express claims, regardless of disclaimers.

In FTC v. POM Wonderful LLC (2013), the Commission found that advertising combining antioxidant mechanism claims with disease-specific research citations created implied disease treatment and prevention claims, even though no individual statement expressly claimed to treat or cure a disease. The Commission's order required POM's future disease treatment and prevention claims to be supported by two randomized, well-controlled human clinical trials — a higher bar than POM's existing evidence could satisfy. On appeal, the D.C. Circuit affirmed the deceptive-advertising finding but vacated the two-trial requirement, holding that one randomized, well-controlled human clinical trial was the appropriate standard for POM's future disease-related claims; the FTC confirmed this outcome in a public statement following the ruling (POM Wonderful LLC v. FTC, 777 F.3d 478 (D.C. Cir. 2015)). The case still establishes, and remains good law for, the principle that aggregated advertising communications are evaluated in totality and that the implied message a campaign creates can exceed what any individual element states; the specific number of trials required is decided case by case rather than fixed at two.

4.4 International Visibility of Digital Advertising

Website content and social media are globally accessible. A brand whose website makes structure/function claims compliant with FDA requirements may simultaneously be presenting those claims to consumers in the EU, UK, Canada, and other jurisdictions where the applicable standard for health claims is materially different. In the EU, displaying a health claim on a website accessible to EU consumers may constitute a claim under Regulation 1924/2006, requiring EU authorization. The manufacturer's intent to target US consumers does not insulate the brand from scrutiny under the laws of jurisdictions where the website is accessible, particularly where significant sales into those jurisdictions occur.

5. Retailer Substantiation Requirements

Regulatory compliance with FDA and FTC standards defines the minimum threshold for lawful commercial activity, not the complete picture of substantiation requirements. Major retail partners maintain supplier qualification requirements that in many cases exceed the regulatory minimum, enforced through commercial mechanisms — de-listing, chargeback penalties, and supplier audits.

5.1 Amazon

Amazon's dietary supplements policy requires that products making health-related claims have third-party laboratory testing documentation confirming the product meets its label claim for declared active ingredients at the stated dose. This means a certificate of analysis from an accredited third-party laboratory — not internal SOPs, not a manufacturer's self-attestation, and not a supplier certificate of analysis for the raw ingredient. The documentation must demonstrate that the finished product, as sold, contains the declared active at the labeled quantity. Amazon also requires cGMP compliance documentation under 21 CFR Part 111 and FDA facility registration. Amazon provides access to a large and willing consumer group, which increases both the commercial importance of the channel and the scale of exposure if a non-compliant product reaches those consumers.

Amazon independently reviews product listings for claims it characterizes as drug claims or unsubstantiated health claims, and has de-listed products for claim violations independent of FDA enforcement action. For brands with material Amazon revenue, de-listing operates as a more immediate and disruptive consequence than a regulatory warning letter.

5.2 Costco

Costco's supplier qualification process for dietary supplements includes product testing through its own third-party testing program, label review for claim compliance, and confirmation of cGMP compliance. Costco has removed products from its shelves following independent testing results that did not support label claims, including in categories where regulatory enforcement had not been initiated. The scale of a Costco de-listing — and the associated chargeback exposure — represents a significant commercial risk that is independent of the regulatory risk profile.

5.3 Whole Foods Market, Sprouts, and The Vitamin Shoppe

Whole Foods Market's Supplier Quality Standards require that products meet a defined set of acceptable and unacceptable ingredient criteria, and that claims be supported by credible scientific evidence and not overstate the evidence base. Whole Foods conducts periodic product audits and requires suppliers to respond to audit findings within defined timeframes.

Sprouts Farmers Market requires suppliers to complete a supplier qualification process that includes third-party certifications relevant to the product category, cGMP compliance documentation, and certificate of analysis documentation for each product. Sprouts has established quality standards that include restrictions on certain ingredient categories and require substantiated claims.

The Vitamin Shoppe maintains a Quality Standards program that includes product testing, supplier audits, and label review. Products sold through The Vitamin Shoppe are subject to periodic third-party testing, and products that fail testing or that make claims not supported by their formulation are subject to removal from the assortment.

5.4 Practical Implications

A substantiation file developed to meet the FDA minimum — a notification and a disclaimer — will not reliably support retail partner qualification, Amazon listing, Costco buyer review, or FTC scrutiny. The most defensible approach develops the substantiation file against the most demanding applicable standard across the product's full commercial lifecycle, with regulatory compliance confirmed as a secondary step.

6. Cross-Border Expansion and International Regulatory Frameworks

The US regulatory framework for structure/function claims under DSHEA has no direct equivalent in most international markets. Substantiation developed for FDA and FTC does not transfer to the EU, UK, Canada, or other major markets.

6.1 EU: Regulation (EC) No 1924/2006

Health claims on food products sold in the EU are governed by Regulation (EC) No 1924/2006. The framework requires pre-authorization for health claims; no equivalent to the US post-marketing notification system exists. EFSA evaluates claims and requires human clinical trial evidence with randomized controlled design, statistical significance, and a demonstrated cause-and-effect relationship in the target population. EFSA has rejected the majority of submitted claims, frequently citing ingredient-form mismatch, dose mismatch, or population mismatch. Authorized claims are published in Regulation (EU) No 432/2012.

6.2 United Kingdom Post-Brexit

The UK maintains a nutrition and health claims register managed by the Food Standards Agency (FSA), substantially reflecting the pre-Brexit EU authorized list as of July 2026, with divergence accumulating. Manufacturers must confirm claim authorization in each jurisdiction separately.

6.3 Canada

Health claims on natural health products (NHPs) in Canada require a pre-market product licence (NPN) from Health Canada under the Natural Health Products Regulations (SOR/2003-196). Claims must be supported by clinical evidence or documented traditional use.

6.4 Cross-Border Shipment and Jurisdictional Accountability

A US-labeled dietary supplement ordered by a consumer in Canada, the EU, or another jurisdiction and shipped internationally is subject in principle to the regulatory requirements of the destination country. Enforcement accountability in cross-border e-commerce is distributed across the manufacturer, the retailer or marketplace platform, and the importer. Amazon's global selling policies require sellers to identify countries where their products may lawfully be sold and shipped, and sellers bear responsibility for ensuring compliance with destination-country requirements.

Manufacturers with meaningful cross-border sales volume should identify the jurisdictions into which their products are being shipped, assess regulatory compliance in those jurisdictions, establish appropriate geographic restrictions in retail and marketplace agreements, and provide retailers with a documented list of authorized distribution countries.

7. Where Brands Get Into Trouble

7.1 Claims That Migrate from Marketing into Labeling Without Review

Marketing language describing product benefits is frequently developed by commercial teams without regulatory review, then incorporated into product labels or advertising. A positioning statement acceptable in a sales deck may constitute a structure/function claim, a disease claim, or an implied efficacy claim when it appears on a label or consumer-facing website. A formal claim review process that applies both FDA label criteria and FTC advertising criteria to all product communications before publication is the primary control against this failure mode.

7.2 Ingredient Substitution and Evidence Gaps

A manufacturer who substitutes a different-sourced ingredient for a clinically studied proprietary ingredient — to reduce cost, address supply issues, or qualify an alternative supplier — while continuing to cite the original clinical evidence has created an evidence gap that the existing substantiation file does not cover. FTC's own compliance guidance walks through this exact fact pattern for a botanical extract: where the marketed product is made with a different extraction method than the studied material and an analysis shows a materially different chemical profile, the advertiser should not rely on the original trials as substantiation (FTC, Health Products Compliance Guidance, 2022, Example 38). NAD's 2023 review of MacuHealth is a real-world instance of the same gap: several of the studies submitted were conducted at ingredient levels different from the marketed product, and none were conducted on the product as currently formulated, which NAD treated as fatal to the claims those studies were offered to support (NAD Case #7226, MacuHealth LP, September 2023). More broadly, botanical extracts that contain different levels or ratios of functional actives between suppliers represent a version of the same problem: two materials meeting the same labeled specification may not be substantiation-equivalent if the ratio or profile of functional actives differs and that profile has been shown to affect activity.

Dose reduction, reformulation into a different delivery system with lower bioavailability, and supplier changes for botanical ingredients should each be treated as substantiation events requiring review of the evidence file and, in many cases, new bridging documentation or new studies.

7.3 The Cumulative Disease Claim Problem

A brand that launches with a defensible structure/function claim may accumulate, through website content, advertising, social media, influencer posts, PR materials, and testimonials, a body of commercial communications that collectively characterizes the product as treating, preventing, or reducing the risk of a disease. A documented example: in 2010, the FTC charged Nestlé HealthCare Nutrition, Inc. over advertising for its children's drink BOOST Kid Essentials, finding that the campaign's television, magazine, and print advertisements collectively conveyed that the product would reduce the risk of colds, flu, and other upper respiratory infections in children — claims requiring FDA disease-claim authorization that the company did not have. The 2010 settlement barred Nestlé from making those claims without FDA approval and required competent and reliable scientific evidence for any future health-benefit claims about its probiotic and nutrition drinks (In re Nestlé HealthCare Nutrition, Inc., FTC File No. 092 3087). Regular review of the complete communications portfolio against the disease claim criteria is necessary to manage this risk over time.

7.4 Outdated Substantiation

A substantiation file adequate at launch may become inadequate as the scientific literature develops, negative studies are published, or systematic reviews revise the weight of evidence. The obligation to maintain adequate substantiation is ongoing. A claim that cannot be supported by the current state of the evidence must be revised or withdrawn; maintaining it constitutes an ongoing violation of the truthfulness requirement.

8. Building a Defensible Substantiation File

A substantiation file's purpose is to defend the product's claims against challenge from regulatory bodies, retail partners, plaintiff attorneys, and competitive complainants. It must document, with rigor, that competent and reliable scientific evidence supports each claim as worded, for the specific product, at the specific dose delivered, in the population the product targets.

8.1 Claim Mapping

Each claim on the product label and in advertising should be identified, categorized (nutrient content, structure/function, or health claim), and documented with a rationale for the category assignment. Claim language at or near the structure/function to disease claim boundary should be flagged for regulatory counsel review before it appears in commerce.

8.2 Evidence Inventory and Assessment

The evidence inventory identifies all relevant studies — supportive and non-supportive. For each study: study design and population; ingredient form, dose, and route of administration; primary and secondary endpoints relevant to the claim; statistical significance and effect size; author-identified limitations; and the assessor's evaluation of the study's relevance to the specific product and claim. Studies conducted on ingredient forms, doses, or populations materially different from the product must be identified and explicitly addressed, not omitted.

8.3 Expert Review

The evidence assessment must be reviewed by a qualified expert with credentials in the relevant scientific disciplines. The expert evaluates methodological quality, assesses relevance to the specific product and claim, identifies limitations and gaps, considers the totality of evidence including negative results, and documents a conclusion as to whether the evidence supports the claim as worded. The expert's curriculum vitae should be included.

8.4 Notification and Disclaimer Documentation

The file should include the FDA structure/function claim notification date, the text of the claim as submitted, and the product name. Label specifications confirming the placement, typeface, size, and wording of the required disclaimer should be retained for each label version in commercial use.

8.5 Laboratory Documentation

Certificate of analysis documentation from an accredited third-party laboratory confirming declared active content at the stated dose in the finished product should be retained for each product and each lot where practical. "Documentation" in this context means an external laboratory report — not an internal SOP, a manufacturing batch record, or a raw material certificate of analysis from the ingredient supplier. The COA must reflect testing of the finished product as sold. Third-party finished product testing is required by Amazon, reviewed by Costco, and expected by major retail buyers.

8.6 When to Consult a Regulatory Attorney

Not every claim decision requires legal counsel, but certain situations materially increase the risk of regulatory or commercial challenge and warrant consultation with an attorney who specializes in dietary supplement regulatory law before the claim appears in commerce:

• Any claim language that references a disease, disease risk, or medical condition, even indirectly or by implication.
• Any claim that will appear in advertising for a product with significant revenue at stake, particularly if the evidence base is not derived from a study conducted on the specific product or ingredient form.
• Any claim in a category where FDA has issued recent warning letters or where FTC has taken recent enforcement action (joint health, cognitive function, immune support, weight management, and cardiovascular health are consistently high-risk categories).
• Any claim for a product being launched into a new international market, where the claim language acceptable under DSHEA may not be permissible under the destination jurisdiction's framework.
• Any response to an FDA warning letter, FTC inquiry, or retailer audit finding that relates to a label claim.
• Any decision about whether to withdraw or revise a claim in response to new scientific evidence.

Regulatory attorneys specializing in dietary supplement law can assess claim language against current FDA and FTC enforcement priorities, review substantiation files for adequacy, and advise on the risk profile of specific claims in specific commercial contexts. The cost of legal review before a claim is published is routinely a fraction of the cost of a regulatory response, retailer de-listing, or litigation after it is.

8.7 Maintenance and Review

The substantiation file should be reviewed at minimum annually, and immediately following any material change to the product formulation, ingredient source, label claims, or commercial communications. The annual review cadence reflects the rate at which the relevant scientific literature, FDA enforcement priorities, and FTC enforcement actions can change materially within a year — and aligns with the standard expected by major retail partner quality programs. Version control should be maintained. Where the scientific literature changes materially, the impact on claim defensibility must be assessed. A claim that can no longer be supported must be revised or withdrawn.

9. Conclusion

Label claim substantiation for finished dietary supplements is a legal obligation that attaches at the moment a claim appears in commerce. The competent and reliable scientific evidence standard requires qualified expert evaluation of evidence specific to the ingredient form, dose, and population the product delivers, covering the totality of the evidence, and applied to claim language that does not exceed what the evidence demonstrates.

The FDA notification and disclaimer requirements for structure/function claims are necessary procedural conditions, not substantive ones. FTC enforcement over advertising applies the same substantiation standard and has produced enforcement actions against products whose labels were within FDA compliance. Retailer qualification requirements impose a further practical layer. Cross-border expansion requires jurisdiction-specific analysis. And the obligation to maintain adequate substantiation is continuous: a claim that cannot be supported by the current state of the evidence must be revised or withdrawn.

Pathway 2 Product provides regulatory substantiation assessment, claim classification review, and development program guidance for nutraceutical ingredient and finished dietary supplement developers. Inquiries may be directed to info@pathway2product.com.